This post contains Amazon affiliate links. If you purchase through them, I earn a small commission at no extra cost to you.

This post is part of the Addiction and Recovery in Primary Care series and its first look at a specific substance. It draws on the first three posts: Most People Get Better Without Us, What the Substance Is Doing, and Before You Ask How Much.


Near the start of Adventures of Huckleberry Finn , Huck asks the Widow Douglas whether he may smoke. She refuses, telling him it is a mean practice and not clean, and that he must try to give it up. His complaint about the lecture is precise: she was “finding a power of fault with me for doing a thing that had some good in it.” Then comes the line that makes the scene: “And she took snuff, too; of course that was all right, because she done it herself.”

Mark Twain supplied the other half of the argument a few paragraphs later, although readers rarely remember it. That same night Huck sits alone in his room, feeling, in his words, “so lonesome I most wished I was dead.” A spider crawls up his shoulder, he flicks it into the candle, and the bad omen leaves him shaking. When the house finally goes still, he gets out his pipe. Nobody in the chapter asks what the pipe was doing for him, even though the answer sits on the page: a lonely, frightened boy found something that steadied him in the dark.

I return to that chapter because it contains both of the failures clinicians tend to bring to tobacco. The first is the widow’s. Her advice is moral rather than clinical, it comes from someone the patient can see through, and it treats the behavior as having no function worth understanding. The second failure is quieter and belongs to the rest of the household, which never notices the pipe at all. Primary care has tended toward the widow’s error, while behavioral health has, for most of its history, tended toward the household’s.

Today is the Great American Smokeout, and this post moves the addiction series ahead to its first specific substance. The earlier posts made three claims: most people who resolve a substance problem do so without formal treatment; substance use is best understood by asking what it is doing for the person; and the context of a patient’s life should be understood before the quantity of use. Tobacco puts all three claims under more pressure than any other substance, largely because it is the one substance primary care already claims as its own.


Two Kinds of Neglect

The U.S. Preventive Services Task Force gives tobacco cessation its highest grade. Its 2021 recommendation asks clinicians to ask every adult about tobacco use, to advise those who use it to quit, and to provide behavioral intervention together with FDA-approved pharmacotherapy for nonpregnant adults . An update is in progress, with a final research plan posted in July 2025, but the 2021 statement remains the current recommendation. It also sits inside a federal quality measure, CMS138, which counts whether adults were screened for tobacco use and, if they use it, whether they received a cessation intervention. By the usual standards of preventive medicine, tobacco has all the attention a condition could ask for.

The national data tell a different story about what happens after the screening question. Among adults who smoked, or had recently quit, and who saw a health professional in 2022, only about half (50.5%) were advised to quit. Among those who tried to quit, 38.3% used counseling or medication. Counseling alone reached 7.3%, and the combination the USPSTF recommends, counseling together with medication, reached 5.3% . I do not read those numbers as indifference on the part of primary care clinicians. They are what measurement tends to do to a workflow: the screening question is quick and auditable, the advice fits in a sentence, and the counseling, which is the part of treatment that takes time, is the part nobody has scheduled. It is also the part a BHC is trained to deliver.

Behavioral health’s record is worse, and it is longer. Prochaska recounts that when the Joint Commission proposed a national ban on smoking in hospitals, two decades before she wrote, mental health advocates argued that tobacco’s calming effect was therapeutic, and psychiatric and drug-treatment units were exempted. Psychiatric hospitals that banned smoking anyway saw little or no disruption in patient behavior. Even so, in her group’s sample of 337 smokers recruited from inpatient psychiatric units, only 4% reported having received help to quit from any health care provider, and some outpatient programs were still using cigarettes as an incentive for treatment compliance. The consequences remain visible. In the 2019–2020 National Survey on Drug Use and Health, 27.2% of adults with serious mental illness smoked, compared with 13.6% of adults with no past-year mental health condition . Among adults with a substance use disorder, smoking prevalence fell from 46.5% in 2006 to 35.8% in 2019, and among adults with both a major depressive episode and a substance use disorder it fell from 50.7% to 37.0% . Those declines are real, and the 2022 cessation data suggest the field has begun to change its habits: adults who smoke and have depression or anxiety are now more likely than other smokers to be advised to quit and to use treatment when they try . The gap in who smokes, however, remains wide.

Two beliefs kept tobacco outside the scope of mental health and addiction treatment for decades. The first held that smoking is a form of self-medication, so that taking it away would destabilize a vulnerable patient. That belief had help, since the tobacco industry funded research and presentations promoting the self-medication hypothesis and marketed cigarettes to people with mental illness . The second held that recovery from alcohol or other drugs should come first, and that tobacco could wait. Both beliefs can be tested, and both have been, with results I take up below.

There is a third form of neglect, which is to treat tobacco use as a choice made in a vacuum. Beginning in the 1960s, the tobacco industry marketed menthol cigarettes to Black urban communities through television and culturally tailored advertising. Drawing on the industry’s own documents, Gardiner traced how that campaign produced a market in which more than 70% of Black smokers preferred menthol, compared with about 30% of White smokers. The targeting has continued with newer products. In 2019, 74.9% of U.S. youth reported exposure to e-cigarette advertising through at least one channel, and non-Hispanic Black and non-Hispanic Asian youth had roughly twice the odds of non-Hispanic White youth of reporting exposure through television . A Federally Qualified Health Center’s panel is, in large part, the population that this marketing was designed to reach. A clinician who understands a patient’s smoking only as a personal failing has accepted the industry’s account of it.


What the Cigarette Is Doing

The second post in this series argued that the most useful clinical question about any substance is what it is doing for the person who uses it, a question that comes from the framework I took up directly two weeks ago in Functional Contextualism in Primary Care Behavioral Health. That second post included a sentence I want to return to here: the patient who smokes when the anxiety becomes unbearable is not weak-willed, but managing something that would otherwise be unmanageable. I still think that is true, and tobacco shows why the sentence needs a second half. Tobacco answers the functional question generously. Patients will tell you that a cigarette calms them, gives them a reason to step outside, marks the end of a meal or a shift, keeps their weight down, and buys five minutes with the coworkers they actually like. Huck’s pipe at midnight belongs on that list as well: the cigarette as company when nothing else is available.

What patients rarely name, because it is hard to see from inside, is how much of that calm is relief from a withdrawal the previous cigarette produced. The Cochrane review by Taylor and colleagues makes this mechanism explicit in its rationale, noting that chronic smoking produces neuroadaptations that generate frequent withdrawal symptoms such as anxiety, irritability, and low mood, so that the cigarette relieving those symptoms is partly treating a state it created. Across the studies that compared changes in mental health between people who quit and people who kept smoking, the reviewers found no evidence that mental health worsens after quitting, along with very low- to moderate-certainty evidence of small to moderate improvements in anxiety, depression, and stress. Those improvements appeared in people diagnosed with mental health conditions as well as in unselected samples.

None of this makes the patient wrong. When she says smoking calms her, she is reporting her experience accurately; she is describing the short arc of a cycle whose long arc she cannot see. The functional stance asks the clinician to take both arcs seriously. Huck was right that his pipe had some good in it, and the clinician’s task is to learn what that good is before deciding what might replace it. This is also why the contextual interview belongs before the quantity questions. In the third post in this series I described the order in which the CI moves through substances, from caffeine to tobacco to alcohol and onward, least stigmatized to most. Tobacco’s place near the front of that sequence is a kindness to the patient, but it carries a risk for the clinician, because the question asked most casually is also the one most easily left without a follow-up. The number of cigarettes a patient smokes each day tells you very little about which of those cigarettes are doing the real work.


Readiness as a Variable

The first post in this series made an argument that applies to tobacco with unusual force: most people who resolve a substance problem do so without formal treatment. The national data bear this out. As of 2015, 59.1% of U.S. adults who had ever smoked had quit, and fewer than a third of smokers who tried to quit that year used counseling or medication to do it . Most attempts to quit, in other words, happen without any formal help. The first post also described the Transtheoretical Model as a map of how self-changers move through stages of readiness, and it is worth remembering whose change process that map was drawn from. DiClemente and Prochaska compared smokers who had quit on their own with smokers who had quit through commercial cessation programs, and the following year Prochaska and DiClemente built their stages of change from a study of 872 people who were changing their smoking on their own. The stages of change that clinicians now apply to every substance began as a description of people putting down cigarettes.

Linda and Mark Sobell, whose self-change research anchored the first post, built a treatment model around the finding that most people change on their own. They developed Guided Self-Change at the Addiction Research Foundation in Toronto, originally for people with alcohol problems, and later brought it to Nova Southeastern University, where it has since been extended to other drugs and to smoking cessation. The model pairs a motivational interviewing style with brief cognitive-behavioral procedures: personalized feedback, a decisional balance, a functional analysis of high-risk situations, self-monitoring, and goals the client sets for herself . The Sobells suggested that the treatment may work largely by speeding up the natural recovery process and providing social support while it unfolds. I learned the model from the inside. As a practicum student in the Guided Self-Change program, I led community smoking cessation groups that the program ran under contract with the Area Health Education Center, and I later managed that group program and supervised the practicum students who led it. Years afterward, with the Sobells’ permission, I adapted the protocol for primary care.

Guided Self-Change also reflects an assumption most of us were trained to hold, which is that treatment follows readiness and that the clinician’s job with an unready patient is to build motivation rather than to offer treatment she has not asked for. Tobacco is where that assumption has been tested most directly. Richter and colleagues randomized 1,000 hospitalized adults who used tobacco to one of two conditions. In opt-in care, patients received treatment if they said they were ready to quit, and patients who were not ready received motivational counseling. In opt-out care, every patient received the full treatment package, including medication, counseling, and follow-up, unless they declined some or all of it. Opt-out care doubled treatment engagement and increased quit attempts, and it left patients reporting a stronger sense of agency and a stronger alliance with their practitioners, which is the opposite of what a concern about coercion would predict. A secondary analysis of the same trial found that, one month after randomization, opt-out patients were more likely than opt-in patients to have quit at every level of baseline desire to quit .

The limits of this trial matter. Its effect on quitting itself was modest and did not last: verified quit rates were 22% versus 16% at one month and 19% versus 18% at six months, and the authors concluded that stronger and longer treatment could increase cessation. The trial also took place at the hospital bedside, with a dedicated tobacco treatment service, among patients who had just been admitted, and a hospitalization is about as close to a natural teachable moment as medicine offers. It does not establish that opt-out care performs the same way in a primary care visit, and it is not a license to pressure anyone. What it does challenge is the idea that readiness is a gate a patient must pass through before treatment is offered. In this trial, readiness behaved more like a variable that treatment could move than a precondition for treatment.

There is less contradiction between this evidence and the Sobells’ model than first appears. Guided Self-Change respects autonomy by letting the patient set the goal and the pace, whereas opt-out care respects autonomy by making refusal as easy as acceptance. Both approaches reject the widow’s posture of moralized advice; where they differ is in what they offer by default. For a BHC in a primary care clinic, I think the opt-out evidence argues for offering more than we usually do (a quit plan, a medication conversation with the PCP, a scheduled follow-up) to patients who have not asked for it, and then honoring whatever answer the patient gives. Nor does this contradict the caution, earlier in this series, against taking away a patient’s way of coping before anything is in place to replace it. An offer of medication, a plan, and a next visit is the something that goes in first.


Sobriety Does Not Need Protecting from This

The belief that tobacco treatment would endanger recovery from alcohol or other drugs deserves its own answer, because it still circulates in treatment programs and in the advice patients receive from peers. The reasoning is familiar. A patient in early recovery has enough to manage, and taking away his cigarettes might push him back toward the substance that brought him into treatment.

The evidence has pointed the other way for two decades. A meta-analysis of 19 randomized trials found that smoking cessation interventions delivered during addictions treatment were associated with a 25% increase in the likelihood of long-term abstinence from alcohol and illicit drugs . The later Cochrane review pooled 34 trials and found that tobacco treatment did not reduce abstinence from alcohol or other drugs. It also reported a finding a BHC should take seriously: in this population, medication alone and medication combined with counseling increased tobacco abstinence, while counseling alone did not reach statistical significance . Prochaska summarized five randomized trials in patients receiving mental health treatment in which quitting smoking did not worsen depression or PTSD symptoms, lead to psychiatric hospitalization, or increase alcohol or illicit drug use. These sources are older than I usually prefer to cite, and I cite them because nothing more recent has displaced them.


What the BHC Brings

None of this requires a tobacco specialist. The USPSTF recommendation notes that counseling combined with medication is more effective than either alone , and the behavioral half of that combination falls squarely within a BHC’s scope. The word that matters there is combined. In a 30-minute visit, that means doing three things well rather than delivering a protocol in full.

The first is the contextual interview, which locates the cigarettes in the patient’s day and identifies the ones doing the most work. The second is coordination with the PCP on pharmacotherapy. Many patients, and some clinicians, still carry the old worry about varenicline and psychiatric symptoms. The EAGLES trial, which enrolled smokers with and without psychiatric disorders, did not show a significant increase in neuropsychiatric adverse events attributable to varenicline or bupropion relative to nicotine patch or placebo, and varenicline was the most effective of the three medications . The trial was funded by the two drugs’ manufacturers, which readers should know, but it was double-blind, placebo-controlled, and enrolled more than 8,000 smokers. That December, the FDA removed the boxed warning about serious mental health side effects from varenicline’s label and removed the corresponding smoking-cessation language from bupropion’s boxed warning. A BHC who can say this plainly to a patient with depression removes one of the most common reasons she gives for declining medication. The third is the follow-up visit itself, which primary care can schedule in ways specialty programs often cannot, and which allows a lapse to become information rather than the end of an attempt. Quitlines (1-800-QUIT-NOW) extend that support between visits (GATHER: Team-based—the BHC supplies the behavioral half of treatment while the PCP prescribes the medication half; 4 Cs: Continuity—a lapse becomes information when the next visit is already on the calendar ).

Patients will also ask about vaping, and the two most authoritative sources do not say the same thing. The USPSTF concluded in 2021 that the evidence was insufficient to assess the balance of benefits and harms of e-cigarettes for cessation in adults . The Cochrane Tobacco Addiction Group’s living review, updated in 2026 with searches through January of that year, now reports high-certainty evidence that nicotine e-cigarettes increase quit rates compared with nicotine replacement therapy, on the order of four additional quitters per 100, while noting that longer and larger trials are still needed to evaluate safety and that its findings apply to regulated nicotine products rather than illicit devices or those containing THC . Part of the disagreement is timing, since the trial evidence has grown considerably since the Task Force’s review and the Task Force’s update is in progress. A BHC does not need to settle that disagreement to be useful. She needs to know which product the patient is using, what it is doing for him, and whether he intends it as a route off cigarettes or as a second source of nicotine.

How a full course of brief treatment fits into primary care is a subject for a later post, which will draw on Guided Self-Change and on the primary care version of the protocol I built.


The Widow’s Snuff

Huck’s complaint about the widow ends with an observation worth keeping: “That is just the way with some people. They get down on a thing when they don’t know nothing about it.” The widow was right that tobacco would hurt him, and wrong to think that settled the matter. Her advice failed because it skipped the question of what the pipe was for, and because it came from someone with a snuffbox of her own and no curiosity about his loneliness.

A BHC can do what neither the widow nor the rest of that household managed. She can ask what the cigarette has been doing, believe the answer, and then offer something better than a sermon: treatment that works, offered as a matter of course, to a patient who remains free to decline it. On the Great American Smokeout, that seems a better gift than one more reminder to quit.


This post was written by the author. Claude (Anthropic) assisted with research, citation verification, and drafting. All clinical content, interpretations, and recommendations reflect the author’s own professional judgment.

References

{2686279:5DAMJS83};{2686279:VYMGJPGQ};{2686279:FF78MYZT};{2686279:J4J7VGZZ};{2686279:HPJ82Q3M};{2686279:T6DEBLVY};{2686279:FF78MYZT};{2686279:J4J7VGZZ};{2686279:FSGZISDK};{2686279:8HHNKRCC};{2686279:T7YHMEDJ};{2686279:KXZH3ELG},{2686279:GS846P3W};{2686279:IWIA399I};{2686279:XEY6FF3Q};{2686279:HYTLMBHC};{2686279:KTEQWVAS};{2686279:M3NWJ8P5};{2686279:PR88QZ9C};{2686279:7ZNUQWXQ};{2686279:B4F9P336};{2686279:FPIAAAF3};{2686279:J4J7VGZZ};{2686279:VYMGJPGQ};{2686279:LC2CP5BS};{2686279:P4ZSFFWY},{2686279:IYCRLCKX},{2686279:7PG2FUKJ};{2686279:VYMGJPGQ};{2686279:B9CR9996} apa default asc 1 0 29586

____________________________________________________
Cite this article as:
Robert Allred, "A Thing That Had Some Good in It: Tobacco in Primary Care Behavioral Health," Allred Consulting, November 19, 2026, https://allred.consulting/2026/11/a-thing-that-had-some-good-in-it-tobacco-in-primary-care-behavioral-health/.

or

APA Style, 7th Edition:
Allred, R. (November 19, 2026). A Thing That Had Some Good in It: Tobacco in Primary Care Behavioral Health. Allred Consulting. https://allred.consulting/2026/11/a-thing-that-had-some-good-in-it-tobacco-in-primary-care-behavioral-health/

Bluesky Discussion

View on Bluesky

No replies yet. Be the first to comment on Bluesky!


Discover more from Allred Consulting

Subscribe to get the latest posts sent to your email.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.